Summary
- Elite Pharmaceuticals is poised to address a sizeable share of abuse deterrent opioid market.
- Drug trials continue to deliver the expected positive results.
- Continued growth and expansion of generic and other drug business.
- Significant leadership additions made to take the company to critical mass.
The truth is that Elite Pharmaceuticals is poised to make a play for a significant and diverse share of the entire $7 billion U.S. opioid market. Globally, the pain med market is $50 billion. To quote Peter Lynch:
Often, there is no correlation between the success of a company's operations and the success of its stock over a few months or even a few years. In the long term, there is a 100 percent correlation between the success of the company and the success of its stock. This disparity is the key to making money; it pays to be patient, and to own successful companies.READ MORE (must have Seeking Alpha account to continue reading article.)
No comments:
Post a Comment